Halozyme Therapeutics (NASDAQ:HALO) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded Halozyme Therapeutics to “strong buy” from “hold,” contributing to a consensus “Moderate Buy” rating and an average price target of $96.50.
• Halozyme reported strong quarterly results, with EPS of $2.28 beating estimates by $0.49 and revenue rising 47.7% year over year to $481 million. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Institutional investors own 97.79% of the company and made significant recent purchases, while insiders sold 125,852 shares worth about $13.5 million over the past 90 days.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) was upgraded by research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a note issued to investors on Tuesday, Zacks reports.

HALO has been the topic of several other reports. Wall Street Zen raised Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Leerink Partners raised Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. TD Cowen upped their target price on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the company a "neutral" rating in a report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.50.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $116.82 on Tuesday. The firm has a market cap of $13.26 billion, a P/E ratio of 34.87, a PEG ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $119.21. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a 50 day moving average of $107.97 and a 200 day moving average of $84.24.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period last year, the business posted $1.54 EPS. The company's revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts expect that Halozyme Therapeutics will post 8.31 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Matthew Posard sold 5,230 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $108.54, for a total transaction of $567,664.20. Following the transaction, the director directly owned 53,609 shares of the company's stock, valued at $5,818,720.86. This represents a 8.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 125,852 shares of company stock worth $13,538,046. Insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $196,540,000. Jupiter Topco LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $105,570,000. Caisse de depot et placement du Quebec purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $83,940,000. Finally, Congress Asset Management Co. boosted its holdings in Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock worth $251,890,000 after buying an additional 1,052,509 shares during the period. Institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.